The vector of anti-EGFRvIII chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFRvIII. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFRvIII antibody linked to FcεRIγ signaling domains. And the vector product was designed for the treatment of glioma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-MZ005||Anti-EGFR (Cetuximab) h(CD3ζ) CAR, pCDCAR1|
|CAR-MZ163||Anti-EGFR (R1) h(CD3ζ) CAR, Pcdcar1|
|CAR-MZ028||Anti-EGFRvIII (RAbDMvIII) h(ICOS-CD3ζ) CAR, pCDCAR1|
|CAR-MZ079||Anti-EGFRvIII (Y10) h(41BB-CD3ζ) CAR, pCDCAR1|
|CAR-MZ164||Anti-EGFR (R1) h(41BB-CD3ζ) CAR, Pcdcar1|
|VP-CAR-LC835||Lenti-EGFRvIII CAR (scFv-DAP12, MR1.1) Viral Particle|
|CAR-MZ078||Anti-EGFRvIII (Y10) h(CD28-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC782||Lenti-EGFRvIII CAR (scFv-CD28-OX40-CD3ζ, MR-1) Viral Particle|
|CAR-T-2-M315-4Z||Anti-EGFRvIII scFv h(CD4-CD3ζ) CART, pCDCAR1|
|CAR-MZ012||Anti-EGFR (Nimotuzumab) h(CD28-41BB-CD3ζ) CAR, pCDCAR1|
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved